About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Philadelphia | 20,904 Studies Near You | Clareo Health

Clinical Trials LocationsPhiladelphia

Clinical Trials in Philadelphia

Discover 20,904 clinical trials near Philadelphia, Pennsylvania. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 20641-20660 of 20,904 trials

COMPLETEDPhase 2< 1 mile

Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer

NCT00054886

The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.

Kidney Neoplasms

Pfizer63 participantsStarted Jan 2003

Los Angeles, California, United States • Mission Hills, California, United States • Monterey Park, California, United States +12 more locations

COMPLETEDNA< 1 mile

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

NCT00012558

A long-term study of current treatments for bipolar disorder, including medications and psychosocial therapies.

Bipolar Disorder

National Institute of Mental Health (NIMH)5,000 participantsStarted Sep 1998

Stanford, California, United States • Denver, Colorado, United States • Boston, Massachusetts, United States +8 more locations

Find Trials by Condition in Philadelphia

Breast Cancerin Philadelphia Lung Cancerin Philadelphia Prostate Cancerin Philadelphia Colorectal Cancerin Philadelphia Melanomain Philadelphia Leukemiain Philadelphia Lymphomain Philadelphia Pancreatic Cancerin Philadelphia Ovarian Cancerin Philadelphia Brain Cancerin Philadelphia

Data from ClinicalTrials.govTerms

COMPLETEDPhase 2< 1 mile

A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer

NCT00051051

CI-1033 is an experimental drug that acts as an inhibitor of erbB (EGFR) receptors, which may be involved in tumor growth. The primary objective of this study is to assess the antitumor activity of CI-1033 in patients with metastatic breast cancer. Patients with histologically confirmed metastatic (Stage IV) breast cancer and who have received no more than 2 prior cytotoxic chemotherapy regimens are eligible for this study. CI-1033 is administered orally. Patients are required to have blood tests periodically while receiving treatment and will be closely monitored throughout the study for possible side effects and response to treatment. Patients may not have received any prior treatment with other agents that target erbB receptors, including Herceptin (trastuzumab) or Iressa (gefitinib).

Breast Neoplasms

Pfizer168 participantsStarted Dec 2002

Montgomery, Alabama, United States • Arroyo Grande, California, United States • Montebello, California, United States +63 more locations

COMPLETEDPhase 4< 1 mile

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

NCT00327691

The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.

Cardiovascular DiseaseCerebrovascular AccidentCoronary Heart Disease

Pfizer8,600 participantsStarted Apr 1998

Alabaster, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +311 more locations

COMPLETEDPhase 1< 1 mile

A Pharmacokinetic Study of Dexmedetomine in Infants

NCT00459082

Blind randomized trial of a single bolus dose of dexmedetomine followed by a continuous infusion (CIVI) for up to 24 hours in infants who immediately post-operative from cardiac surgery and require tracheal intubation with mechanical ventilation in the post-operative period. Three bolus and infusion dose will be administered to a total of 36 patients.

Cardiac Surgical Procedures

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)36 participantsStarted May 2004

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 3< 1 mile

Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects

NCT00255528

This was a 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group study to determine the antihypertensive dose range, efficacy, safety and tolerability of TOPROL-XL ® (metoprolol succinate) extended-release tablets (metoprolol CR/XL) in hypertensive pediatric subjects. The study population included school age children (age 6 to \< Tanner Stage 3) and adolescents (\> Tanner Stage 3 to age 16) of both genders. No more than 50% of the randomized subjects could be adolescents (\> Tanner Stage 3 to 16 years old). Since response to some therapies in adult hypertension appears to be different in black and non-black populations, recruitment was aimed at a mixture of black and non-black children. The design included a 1-week screening period (for treatment naive subjects), a 1-week single-blind placebo run-in period, and a 4-week double-blind treatment period. Eligible subjects were randomized to the double-blind period with a once daily oral dose of metoprolol CR/XL to one of three target doses: 0.2, 1.0 and 2.0 mg/kg, or placebo. Dosing was weight adjusted. The dose range for this study was 12.5 to 200 mg daily. Subjects were closely monitored and evaluated at the end of Weeks 1, 2, 3 and 4 during the double-blind treatment period.

AstraZeneca144 participantsStarted Jul 2002

Little Rock, Arkansas, United States • Bellflower, California, United States • Beverly Hills, California, United States +28 more locations

COMPLETEDPhase 325 miles

US Inhaled Insulin Therapeutic Choice Questionnaire Study

NCT00139763

This is a questionnaire based study (no study drug is involved) that asks if more patients with uncontrolled type 2 diabetes on diabetes pills will choose insulin as the next treatment choice if inhaled insulin were available in addition to all currently available treatments, compared with if inhaled insulin was not available as part of currently available treatments. This study will also ask if patients with uncontrolled type 2 diabetes currently managed on diabetes pills + once daily insulin will choose as the next treatment choice to take insulin multiple times a day if inhaled insulin were available in addition to all currently available treatments, compared with if inhaled insulin was not available as part of currently available treatments.

Diabetes Mellitus, Type 2

Pfizer740 participantsStarted Jul 2005

Chandler, Arizona, United States • Mesa, Arizona, United States • Phoenix, Arizona, United States +39 more locations

COMPLETEDPhase 275 miles

TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment

NCT00140309

This study is a placebo-controlled factorial study, randomized to study drug (moxifloxacin vs. ethambutol) and treatment frequency (daily vs. thrice weekly after an initial two weeks of daily therapy) during the first two months of standard treatment (with isoniazid, rifampin, and pyrazinamide) for sputum smear-positive pulmonary tuberculosis.

Tuberculosis, Pulmonary

Centers for Disease Control and Prevention350 participantsStarted Jul 2003

Los Angeles, California, United States • San Diego, California, United States • San Francisco, California, United States +20 more locations

COMPLETEDPhase 380 miles

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

NCT00039910

Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has been demonstrated to increase platelet counts. This study will test the safety and efficacy of the investigational drug in the prevention of thrombocytopenia in patients with recurrent or refractory intermediate-grade or high-grade non-Burkitt's, non-Hodgkin's lymphoma (NHL), or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine, and Cisplatin) chemotherapy.

Non-Hodgkin LymphomaHodgkin DiseaseThrombocytopenia

Pfizer240 participantsStarted Jul 2000

Phoenix, Arizona, United States • La Jolla, California, United States • Loma Linda, California, United States +35 more locations

COMPLETED81 miles

De-Medicalizing Mifepristone Medical Abortion

NCT00120224

This study will investigate the possibility that medical abortion using mifepristone and misoprostol - a safe, proven therapy for terminating early first trimester pregnancy - can be administered in a manner that is simpler and less costly than that routinely employed in the United States. The researchers hypothesize that: 1. Practitioners themselves, based on history and examination but without sonography, are able to dependably and correctly determine which patients are eligible for medical abortion and which patients either are not eligible or require further evaluation to determine eligibility. 2. Practitioners themselves, based on a symptom diary and low-sensitivity pregnancy test but without sonography, are able to dependably and correctly determine when a successful medical abortion has taken place and when referral for other possible outcomes should be made. 3. A symptom diary and low-sensitivity pregnancy test are safe and effective means of separating those women who could benefit from a follow-up visit from those who do not need one.

Medical Abortion

Gynuity Health Projects4,410 participantsStarted May 2005

San Diego, California, United States • Chicago, Illinois, United States • New York, New York, United States

COMPLETEDPhase 481 miles

Quick Start Approach to Birth Control Pills

NCT00068848

Women who choose to take birth control pills are currently instructed to begin taking the pills at the end of a menstrual cycle. This creates a window of time between when the woman is given the pills and when she begins taking them. Some women fail to begin taking the pills, placing them at increased risk of pregnancy. This study will evaluate a new approach to beginning birth control pills. Women will take the first pill in the doctor's office rather than waiting until the next menstrual cycle.

PregnancyContraception

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2,000 participantsStarted Feb 2003

Atlanta, Georgia, United States • New York, New York, United States • Dallas, Texas, United States

UNKNOWNPhase 481 miles

Buprenorphine and Integrated HIV Care Evaluation

NCT00124358

The purpose of this study is to assess the feasibility, cost and effectiveness of interventions designed to integrate buprenorphine treatment for opioid dependence into HIV primary care in ten HIV care centers in the U.S.

Opioid-Related DisordersHIV InfectionsAIDS

The New York Academy of Medicine1,350 participantsStarted Aug 2005

Tucson, Arizona, United States • Oakland, California, United States • San Francisco, California, United States +7 more locations

COMPLETED95 miles

Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk

NCT00192439

\- Estimate the incidence rate of hMPV infection detected by RT-PCR from frozen nasal wash aspirates in children at high risk for severe LRI disease (hospitalized at \<2 years of age).

Severe Respiratory Disease

MedImmune LLC1,500 participantsStarted Dec 2003

Long Beach, California, United States • Denver, Colorado, United States • Chicago, Illinois, United States +21 more locations

TERMINATEDPhase 295 miles

Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome

NCT00351221

The trial will investigate the treatment of growth failure in children with Noonan syndrome. Abnormalities in the growth hormone (GH) - insulin-like growth factor-I (IGF-I) axis resulting in low IGF-I levels have been suggested as a possible cause of short stature seen in Noonan syndrome children. Administration of our investigational product is intended to bypass the abnormalities in the GH-IGF axis, and hopefully improve body growth.

Noonan Syndrome

Insmed Incorporated24 participants

New Hyde Park, New York, United States • Columbus, Ohio, United States

UNKNOWNPhase 299 miles

RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease

NCT00385385

The objective of this study is to evaluate an antibiotic therapy called Rifalazil to determine its effect on hardening of the carotid arteries.

Coronary Artery DiseaseCerebrovascular DiseasePeripheral Vascular Disease

ActivBiotics72 participantsStarted Oct 2006

Lansing, Michigan, United States • Roslyn, New York, United States • Stony Brook, New York, United States +3 more locations

COMPLETED114 miles

VIBRANT Registry: Value of Information Based From Pacemaker Recordings and New Technologies

NCT00294034

The purpose of this study is to collect data from pacemakers and determine how this information is used by physicians to care for their patients with pacemakers.

PacemakerBradycardia

Medtronic Cardiac Rhythm and Heart Failure950 participantsStarted Oct 2002

Hot Springs, Arkansas, United States • Little Rock, Arkansas, United States • North Little Rock, Arkansas, United States +24 more locations

UNKNOWNPhase 1123 miles

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

NCT00462189

RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia(HCL) that has not responded to chemotherapy, surgery or radiation therapy. PURPOSE: Phase I dose escalation study to determine the maximum tolerated dose of CAT-8015 immunotoxin in treating patients who have hairy cell leukemia (HCL) that has not responded to treatment.

LeukemiaHairy Cell LeukemiaHCL

Cambridge Antibody Technology40 participantsStarted Apr 2007

Stanford, California, United States • Chicago, Illinois, United States • Bethesda, Maryland, United States +2 more locations

UNKNOWNPhase 1123 miles

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

NCT00457860

RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be an effective treatment for chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), or small lymphocytic lymphoma (SLL that has not responded to chemotherapy, surgery or radiation therapy. PURPOSE: Phase I dose escalation study to determine the maximum tolerated dose of CAT-8015 immunotoxin in treating patients who have chronic lymphocytic leukemia, prolymphocytic leukemia or small lymphocytic lymphoma that has not responded to treatment

Cambridge Antibody Technology50 participantsStarted Mar 2007

Beverly Hills, California, United States • Indianapolis, Indiana, United States • Bethesda, Maryland, United States +1 more locations

TERMINATEDPhase 2339 miles

Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia

NCT00159640

The purpose of this study is to determine the effectiveness of PD-217,014 in the treatment of chronic pain following a shingles infection.

Pfizer315 participantsStarted Feb 2004

Warrawong, New South Wales, Australia • Westmead, New South Wales, Australia • Kippa-Ring, Queensland, Australia +29 more locations

UNKNOWNPhase 21115 miles

Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)

NCT00449202

The purpose of this study is to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day cycles of escalating oral doses of MP 101 in 100 obese adult subjects.

Manhattan Pharmaceuticals100 participantsStarted Jun 2006

Baton Rouge, Louisiana, United States • Salt Lake City, Utah, United States • Basel, Switzerland

PreviousPage 1033 of 1046Next

Diabetes

in Philadelphia

Heart Diseasein Philadelphia